For the Inventor, By the Inventor

Enter assignee name

Pleasanton, CA, United States of America

Neotract, Inc.

USPTO Granted Patents = 68

EPO Patents = 11

Trademarks = 9

Forward Citations = 6,205

Loading Chart...

Loading Chart...

56 inventors (with patents filed for the assignee):

Joseph Catanese, Iii (64 out of 85 patents)

Theodore Charles Lamson (56 out of 94 patents)

Joshua Makower (38 out of 274 patents)

4. Floria Cheng (29 out of 37 patents)

5. Michael Collinson (29 out of 46 patents)

6. Claude A Vidal (29 out of 58 patents)

7. Russell J Redmond (29 out of 82 patents)

8. Daniel Merrick (26 out of 30 patents)

9. Matthew McLean (25 out of 44 patents)

10. Jacqueline Nerney Welch (24 out of 27 patents)

11. Amik Nagpurkar (19 out of 19 patents)

12. Amrish Jayprakash Walke (17 out of 70 patents)

13. Ling-Kang Tong (16 out of 22 patents)

14. Brian Y Tachibana (14 out of 23 patents)

15. Michael Gearhart (13 out of 18 patents)

Core Competencies:

Anchor Delivery System

Benign Prostatic Hyperplasia

Tissue Manipulation

Latching Anchor Device

Median Lobe Destruction

Suture Anchoring Devices

Multi-Actuating Trigger

Flexible Anchor Delivery

Incontinence Treatment

Coiled Anchor Device

Median Lobe Band Implant

Continuous Indentation Apparatus

68 patents: Sort by Forward Citations

1. 11129608 - Anchor delivery system (2021-09-28),

2. 11090036 - Devices, systems and methods for treating benign prostatic hyperplasia and other conditions (2021-08-17),

3. 10945719 - Devices, systems and methods for retracting, lifting, compressing, supporting or repositioning tissues or anatomical structures (2021-03-16),

4. 10925587 - Anchor delivery system (2021-02-23),

5. 10912637 - Devices, systems and methods for treating benign prostatic hyperplasia and other conditions (2021-02-09),

6. 10702261 - System with reloadable handle for delivering an anchor (2020-07-07),

7. 10575844 - Devices, systems and methods for treating benign prostatic hyperplasia and other conditions (2020-03-03),

8. 10492792 - Devices, systems and methods for treating benign prostatic hyperplasia and other conditions (2019-12-03),

9. 10426509 - Median lobe destruction apparatus and method (2019-10-01),

10. 10349932 - Anchor delivery system (2019-07-16),

11. 10299780 - Apparatus and method for manipulating or retracting tissue and anatomical structure (2019-05-28),

12. 10292801 - System for delivering anchors for treating incontinence (2019-05-21),

13. 10265061 - Latching anchor device (2019-04-23),

14. 10201343 - System for delivering an anchor (2019-02-12),

15. 10195014 - Devices, systems and methods for treating benign prostatic hyperplasia and other conditions (2019-02-05),

NeoTract, Inc. develops innovative medical devices aimed at enhancing urological care. The company's primary product, UroLift System, provides a minimally invasive treatment for patients with lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). NeoTract's mission is to improve the lives of those suffering from urological conditions through the development of safe and effective solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

68 Patents

#14 in Pleasanton, CA

#1,222 in California

#5,146 in US

#10,446 in the World

Pleasanton, CA, United States of America

Neotract, Inc.

Forward Citations = 6,205

56 inventors:

Joseph Catanese, Iii (64 out of 85 patents)

Theodore Charles Lamson (56 out of 94 patents)

Joshua Makower (38 out of 274 patents)

4. Floria Cheng (29 out of 37 patents)

5. Michael Collinson (29 out of 46 patents)

Please report any incorrect information to support@idiyas.com

Loading…